News Posts List
Biomedical Researcher Gets $1.9 Million To Study Influenza Vaccines
07/31/2017
ATLANTA—Dr. Sang-Moo Kang, professor in the Institute for Biomedical Sciences at Georgia State University, has renewed a four-year, $1.9 million federal grant to develop influenza vaccines that offer enhanced protection against a broad range of influenza virus strains.
New Workflow Is First End-to-End Solution For Extrusion-Based Drug Implant Production
07/27/2017
Thermo Scientific Pharma mini implant line is an automated, integrated system designed for continuous production of drug implants
NIH Awards NeurOp $3.5 Million to Support Phase 1 Clinical Trial of NMDA Inhibitor NP10679
07/24/2017
NP10679 is in development to prevent brain ischemia during stroke or subarachnoid hemorrhage
Skin Vaccination with Microneedle Patch, Influenza Fusion Protein Improves Efficacy of Seasonal Flu Vaccines, Study Finds
07/19/2017
ATLANTA—A boosting skin vaccination with a biodegradable microneedle patch and protein constructed from sequences of influenza virus subtypes could improve the effectiveness of conventional influenza vaccines, according to a study led by Georgia State University.
Tech Square Labs scores $1 million from Invest Georgia
07/13/2017
Atlanta-based Tech Square Labs Fund has received a $1 million investment from Invest Georgia, a state-run venture capital fund.
AdvaMed Urges House Passage of MDUFA Reauthorization Bill
07/11/2017
WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) issued the following statement from President and CEO Scott Whitaker regarding the planned vote in the U.S. House on the FDA Reauthorization Act of 2017:
Medical device company raises $12.3 million, plans move to Atlanta
07/11/2017
Dune Medical Devices, a metro Philadelphia-based company dedicated to identifying microscopic residual cancer, is moving its U.S. headquarters to Atlanta.
BIO Adopts Principles on Workplace Development, Diversity, and Inclusion; Launches Board WDDI Commit
07/05/2017
WASHINGTON--(BUSINESS WIRE)--Today, the Biotechnology Innovation Organization (BIO) released a set of principles on workforce development, diversity, and inclusion (WDDI) for the biotechnology industry. Concurrent with the adoption of these principles, BIO established a board-level WDDI Committee charged with working to foster workforce development, diversity, and inclusion at BIO and throughout the biotech industry. The Committee will be chaired by Helen Torley, President & CEO of Halozyme, who is succeeding Julie Gerberding, Executive Vice President & Chief Patient Officer at Merck, who led the Committee as it developed BIO’s WDDI principles over the last year.
It’s a Wrap-BIO 2017 Delivers Again
07/05/2017
Breaking all previous records, BIO 2017 hosted over 41,400 partnering meetings during this year’s event. Facilitated by BIO’s unique One-on-One Partnering™ system, these invaluable connections form the foundation of innovative industry collaborations and scientific breakthroughs. That word—breakthrough—was heard and seen throughout the Convention Center in San Diego from June 19 – 22. “Breakthrough” reflects the innovation and exciting advancement in the biotech sector.
One Health Holds the Key to Preventing the Next Pandemic
07/05/2017
Can we combat disease threats before they even emerge? In the fight against infectious diseases, understanding where outbreaks are most likely to happen and under which circumstances can help us develop tools to address risk to potentially prevent the next pandemic.
News Feed